Pharmacologic manipulation of human erythrocyte 2,3-diphosphoglycerate levels by prednisone administration.
Erythrocyte 2,3-diphosphoglycerate (2,3-DPG) concentrations in 10 patients with acute lymphoblastic leukemia rose 21.3%(P smaller than 0.02) after 3 weeks of prednisone and vincristine therapy, and returned to pretreatment level 2 weeks after therapy had been discontinued. The mean 2,3-DPG level of three patients on vincristine alone did not vary significantly from the control level of the leukemia patients on prednisone and vincristine. No significant change in serum inorganic phosphate level was observed. The mean erythrocyte 2,3-DPG concentration of 17 nephrotic syndrome patients being treated with chronic prednisone therapy was 14.0% higher than a control group of 20 nephrotic syndrome patients not being treated with prednisone (P small than 0.01). A significant positive correlation was observed between the dose of prednisone and 2,3-DPG level.
D002648:Child; D002986:Clinical Trials as Topic; D004163:Diphosphoglyceric Acids / Q000097:blood*; D004305:Dose-Response Relationship, Drug; D004912:Erythrocytes / Q000378:metabolism*; D005260:Female; D006400:Hematocrit; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007945:Leukemia, Lymphoid / Q000097:blood / Q000188:drug therapy; D008297:Male; D009404:Nephrotic Syndrome / Q000097:blood / Q000188:drug therapy; D010101:Oxygen Consumption / Q000187:drug effects; D010710:Phosphates / Q000097:blood; D011241:Prednisone / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D014750:Vincristine / Q000008:administration & dosage / Q000627:therapeutic use
D004163:Diphosphoglyceric Acids; D006454:Hemoglobins; D010710:Phosphates; D014750:Vincristine; D011241:Prednisone